SlideShare a Scribd company logo
Faster Media,
Faster Outcomes
Faster Media, Faster Outcomes
12/4/2020 // confidential
2
Faster Media, Faster Outcomes
Previous webinar: Better Media, Better
Outcomes (available to view on Nucleus
Biologics’ website)
Today: Faster Media, Faster Outcomes
Future webinar: Intelligent Media
Formulation Using Machine Learning
2
Faster Media, Faster Outcomes
12/4/2020 // confidential
3
Who We Are
David Sheehan
Founder and CEO
Nucleus Biologics
Roddy O’Connor, Ph.D
Research Assistant
Professor
University of Pennsylvania
Alex Klarer
Head of CellTherapy
Development
BioCentriq
David Smith Ph.D
VPTechnical
Operations
Ori Biotech
Faster Media, Faster Outcomes
12/4/2020 // confidential
4
September Webinar Recap
Media Can Be a Competitive Advantage in Your Therapy Development
Perceived Impediments to Custom
Cost?
Development time?
Expertise?
Faster Media, Faster Outcomes
512/4/2020 // confidential
Custom Media vs. Proprietary Off-the-Shelf Media (POTS)
Custom
• Built based on ingredients specified by scientist.
• Can start with common basal media formulation or be completely custom.
• Will usually be optimized to the unique attributes of the therapy company’s
ecosystem.
POTS
• Cell-specific media developed by media manufacturer.
• Formula is secret both in composition and concentration.
• Formula can only be augmented by the user at the point of manufacturing.
Faster Media, Faster OutcomesFaster Media, Faster Outcomes
6
Media is a Critical Part of Your Therapy Ecosystem
The dilemma of
media choice in
cell and gene
therapy
POTS
Unknown
ingredients, not
your IP, sole
sourced
Fast regulatory,
supposedly in-
stock
Custom media
6 month+ lead
time, difficult to
iterate
Own the media,
know every
ingredient
Faster Media, Faster Outcomes
What is the Development Cycle and Cost?
12/4/2020 // confidential
7
Research POTS
Suppliers
Order and Delivery4 weeks
Media
Testing/Development w/
and w/Out Supplemental
Reagents
Order Additional
Reagents to Test, and
Delivery
4 weeks
>> Ready to order, off the shelf
media w/ additional reagents added
at point of use
Media
Testing/Development
w/ and w/out
Supplemental
Reagents
2 weeks
6 weeks
6 weeks
Place Order – Delivery 2
Weeks
Configuration and
quoting
Media
Testing/Development
Configuration and
quoting
6 weeks
Manufacturing
Research Components4 weeks
20
weeks
6 weeks
Manufacturing20
weeks
6 weeks
Faster Media, Faster Outcomes
Traditional Custom Media
development cycle is 1 year
Traditional
Custom
POTS
12/4/2020 // confidential
8
POTS Formulation - Trial and Error
The number of conditions tested goes up with POTS because the formulations are unknown
Companies
Thermo
Lonza
Miltenyi
Irvine Scientific
R&D Systems
STEMCELLTechnologies
Cellgenix
Reagents
IL-2
IL-7
IL-15
Serum
Physiologix
HEPES
Glutamine
Faster Media, Faster Outcomes
Thousands of test conditions to look at without
knowing what is in the basal media you are using
Testing 7 reagents
creates 125 unique
combinations and that
doesn’t count
concentration changes.
Multiply that by the
number of basal media
tested
12/4/2020 // confidential
Media Supplier
Configuration and
quoting
Research Suppliers
Small Lot
Manufacturing
4 weeks
Nucleus, a
New Model for
Custom
POTS
Research Components 2 weeks
Media
Testing/Development
6 weeks
Configuration and
quoting
Small Lot
Manufacturing
4 weeks
Order and Delivery
From Multiple
Suppliers
4 weeks
Media
Testing/Development w/
and w/Out Supplemental
Reagents
Order Additional
Reagents to Test, and
Delivery
4 weeks
6
minutes
Media
Testing/Development
6 weeks
>> Ready to order, scale
production of custom media in
any packaging required
>> Ready to order, off the shelf
media w/ additional reagents added
at point of use
Media
Testing/Development
w/ and w/out
Supplemental
Reagents
It now takes the same amount of time to develop custom media as
it does to create a formulation based on proprietary media
2 weeks
6 weeks
6 weeks
Faster Media, Faster Outcomes
22
weeks
OK, development time is equal
but what about cost?
12/4/2020 10
11
Brand Media $/L Protein Reagents Total
OpTmizer $166 $100 (serum at 5%) $20 (Il7, IL15) $286
XVivo
Therapeak
$182 $100 (serum at 5%) $20 (Il7, IL15) $302
Immunocult $320 $320
TexMACS $170 $100 (serum at 5%) $20 (IL7, IL15) $290
Average $299.50
Accounting for Media - $299.50/L for POTS
Faster Media, Faster Outcomes
12/4/2020 // confidential
12
Base Medium
(X-Vivo, OpTmizer)
Reagents (IL-2,
IL-15)
Protein
(HSA, Human AB)
POT
S
NB-Lux
$
$
$ $
$ $ $$166
$20
$100
$299.50 + Labor +Waste / Liter $189 / Liter @ 200L
$470/ Litter @ 2L
$ $
$$
Cost to Order
Multiple known
basal medias +
reagents you
choose
Test multiple
formulations quickly.
Known basal media +
protein + cytokines
QC:
POTS - each component
Custom - final product
Faster Media, Faster Outcomes
12/4/2020 // confidential
13
Development Costs
Small Lot Custom materials are more expensive, but your labor time drives development costs
0K 20K 40K 60K 80K 100K 120K
NB-Lux
POTS
Cost
Can you go faster if you know the ingredients?
Materials Labor Labor:
Assume 22 weeks
dev time at
$100/hr
Materials:
$26K for Custom
$18K for POTS
Faster Media, Faster Outcomes
12/4/2020 // confidential
14
Lifecycle Costs – POTS 50% Higher Cost than
Custom As You Go Into Commercial Production
$M
$2M
$4M
$6M
$8M
$10M
$12M
$14M
Dev Phase 1 Phase 2 Phase 3 Commercial Low
(#1000)
Commercial High
(#5000)
CUMULAITVECOST
NB-Lux Custom Thermo POTS Lonza POTS
Faster Media, Faster Outcomes
Most biotechs trade at
30X earnings. This is
$120M of company
value
$4M/year
12/4/2020 // confidential
15
Summary So Far…
• Development costs for media are dominated by labor hours not materials
• Development time is the same for NB-Lux as it is for POTS
• At scale production cost of NB-Lux custom media is 33% less than POTS
• If you own the formula, it’s your IP and you control who manufactures it,
the format, and second sources
• Cost of a failed lot - how do you troubleshoot a failed lot if you don’t know
what’s in your media?
At scale production, you’re looking at millions of dollars of cost
differential just for media.
Faster Media, Faster Outcomes
12/4/2020 // confidential
12/4/2020 16
Case Study #1
Faster Media, Faster Outcomes
17
Custom Media is Required to Optimize
your Cell Therapy
Problem Statement:
Inherent limitations with proprietary off-the-shelf media as the impact of
individual components on CART-cell efficacy can’t be studied
The Goal:
The goal was to design medium specifically lacking a single amino acid to test its
contribution to mitochondrial function in CART-cells
Methods:
Design medium lacking arginine using the NB-LUX platform. Supplement this
medium with varying levels of 13C6 arginine
Results:
The final media was easily designed, cost-efficient, and yielded considerable
insights into the role of arginine in CART-cell metabolic function
Faster Media, Faster Outcomes
12/4/2020 // confidential
18
Cancer patient
T cells removal
from a patient
1
Genetic redirection ofT
cells
ex vivo expansion
2
3
Reintroduction of
modifiedT cells
4
Generating CAR-T Cells for Cell-Based Therapies
Faster Media, Faster Outcomes
12/4/2020 // confidential
19
α-ketoglutarate
succinyl-CoA
succinate
fumarate
citrate
oxaloacetate
L-malate
acetyl-CoA
IDH
MD
FH
SD
acetyl-CoApyruvate
PD
Glucose
Citrate
Acetyl CoA
Palmitate
TCA Cycle
13C5 Gln
GlnCO2
13C5 Gln
Using a [U-13C5]-Glutamine Tracer to
Examine Glutamine Metabolism in T Cells
Faster Media, Faster Outcomes
12/4/2020 // confidential
20
0
20
40
60
80
100
%labelinSuccinyl-
CoA
Untreated
13C5 gln Bulk
T
13C5 gln
CD4+
13C5 Glutamine
0
20
40
60
80
100
M+0 M+1 M+2
%labelinacetyl-CoA
pool
Untreated
Bulk T
CD4+
CD8+
13C5 Glutamine
α-ketoglutarate
succinyl-CoA
succinate
fumarate
citrate
oxaloacetate
L-malate
acetyl-CoA
IDH
MD
FH
SD
Citrate
Acetyl CoA
Palmitate
TCA Cycle
13C5 Gln
GlnCO2
How can we optimize the medium for these studies?
Representative data from
O’Connor et al., 2018
Glutamine Supports Mitochondrial
Function in Activated T Cells
Faster Media, Faster Outcomes
12/4/2020 // confidential
21
SY5Y
(1m
M
)
T
cells
(1m
M
)
T
cells
(4m
M
)
0
20
40
60
80
100
%LabeledOrnithine
13C6 L-Arginine
SY5Y
(1m
M
)
T
cells
(1m
M
)
T
cells
(4m
M
)
0
20
40
60
80
100
%LabeledOrnithine
13C6 L-Arginine
Customized Medium Supports Our Efforts To Determine
The Role of Amino Acids in CAR T-cell Metabolism
Faster Media, Faster Outcomes
12/4/2020 // confidential
22
Custom Media is Required to Optimize
Your Cell Therapy
Conclusion:
Identified the need to have media without certain components to test the
impact on the effectiveness of the CART cells
Solution:
Order small lot Arginine-free media with ease (5 minutes) from NB-Lux
and supplemented it with varying levels to test its role inT cells
Impact:
Performed experiments to show that higher levels play an important role
in metabolic function inCART cells. Expand study to look at other amino
acids. Long term expectation is an advanced formulation for enhanced
CART cell potency.
Faster Media, Faster Outcomes
12/4/2020 // confidential
12/4/2020 23
Case Study #2
Media forVaccines- Formulation to ordering
Faster Media, Faster Outcomes
24
Xeno Free Vaccine Media
Problem Statement:
A biotech generating a novel vaccine was struggling to eliminate animal origin
components from their media without affecting critical quality attributes.
The Goal:
The goal was to maintain proliferation and therapeutic potency with a simple
xeno free media that if possible, also lowered the cost of production.
Methods:
Nucleus Biologics FormulationTeam through a combination of high throughput
screening and experience-based component selection was able to create an
optimized formulation within 2 cycles of testing.
Results:
The final media was AOF, equivalent or slightly better in proliferation and
significantly lower cost. Formulation was transferred to NB-Lux for small lot
ordering.
Faster Media, Faster Outcomes
12/4/2020 // confidential
2512/4/2020
Xeno Free Vaccine Media - Results
2 step process – get rid of animal origin components and then optimize media by
modifying amino acids and other component level changes
Faster Media, Faster Outcomes
26
Developing Custom Media Enables Multifactor Analysis
0
0.5
1
1.5
2
2.5
3
Media A Media B Media C Media D
RELATIVEYIELD
POTS Simulated Results
0% HABS 2.5% HABS 5% HABS 10% HABS
0.0x Glutamine
0.5x Glutamine
1.0x Glutamine
1.5x Glutamine
0
0.5
1
1.5
2
2.5
0.0x
Arginine
0.5x
Arginine
1.0x
Arginine 1.5x
Arginine
RelativeYield
0-0.5 0.5-1 1-1.5 1.5-2 2-2.5
Custom Media Simulated
Results
Faster Media, Faster Outcomes
12/4/2020 // confidential
27
Comparison of Approaches
• Time to develop media was 3 months
• Trial and error testing with POTS
would have been same time
• Removed animal components and
optimized for critical quality attributes
of customer
• Formula now stored on NB-Lux and
can order any size lot in any package
configuration
Faster Media, Faster Outcomes
12/4/2020 // confidential
28
NB-Lux as a Solution For Custom Media
Start small! Use us as validation lots before you order big orders
28
Faster Media, Faster Outcomes
29
If NB Lux development doesn’t take
longer, is less expensive, and is more
optimized, what’s stopping you from
ordering custom media?
Q&A Session
29
Faster Media, Faster Outcomes
Next Webinar:
Intelligent self-guided
formulation services
12/4/2020 // confidential
12/4/2020 30
Thank you!
Connect with us
LinkedIn: www.linkedin.com/company/nucleus-biologics
Twitter: @nucleusbiologic
Faster Media, Faster Outcomes

More Related Content

What's hot

Overview of Global Regulatory Affairs for Gene Therapy 2019
Overview of Global Regulatory Affairs for Gene Therapy 2019Overview of Global Regulatory Affairs for Gene Therapy 2019
Overview of Global Regulatory Affairs for Gene Therapy 2019
Mridula Shukla
 
Get Proactive With Your Stability Program
Get Proactive With Your Stability ProgramGet Proactive With Your Stability Program
Get Proactive With Your Stability Program
Merck Life Sciences
 
The Minute: Volume 11 Issue 1 - Winter 2011
The Minute: Volume 11 Issue 1 - Winter 2011The Minute: Volume 11 Issue 1 - Winter 2011
The Minute: Volume 11 Issue 1 - Winter 2011
The MarkeTech Group
 
Payload Core Product Line Accelerates ADC Clinical Timelines
Payload Core Product Line Accelerates ADC Clinical TimelinesPayload Core Product Line Accelerates ADC Clinical Timelines
Payload Core Product Line Accelerates ADC Clinical Timelines
Merck Life Sciences
 
Process Impurities: Don’t Let PEI or HCP Derail Your BioTherapy
Process Impurities: Don’t Let PEI or HCP Derail Your BioTherapyProcess Impurities: Don’t Let PEI or HCP Derail Your BioTherapy
Process Impurities: Don’t Let PEI or HCP Derail Your BioTherapy
Merck Life Sciences
 
TetraQ - Integrated Preclinical Drug Development Solutions Presentation
TetraQ - Integrated Preclinical Drug Development Solutions PresentationTetraQ - Integrated Preclinical Drug Development Solutions Presentation
TetraQ - Integrated Preclinical Drug Development Solutions Presentation
guest55305
 
Upcoming USP 665 - Level of Characterization of Single-Use Systems Today and ...
Upcoming USP 665 - Level of Characterization of Single-Use Systems Today and ...Upcoming USP 665 - Level of Characterization of Single-Use Systems Today and ...
Upcoming USP 665 - Level of Characterization of Single-Use Systems Today and ...
MilliporeSigma
 
A Molecule’s Journey – Breaking Down Roadblocks to Commercial Success
A Molecule’s Journey – Breaking Down Roadblocks to Commercial SuccessA Molecule’s Journey – Breaking Down Roadblocks to Commercial Success
A Molecule’s Journey – Breaking Down Roadblocks to Commercial Success
MilliporeSigma
 
SMi Group's Drug Discovery 2018
SMi Group's Drug Discovery 2018SMi Group's Drug Discovery 2018
SMi Group's Drug Discovery 2018
Dale Butler
 
Walter King Resume 2015
Walter King Resume 2015Walter King Resume 2015
Walter King Resume 2015
Walter King
 
Streamlining Biopharmaceutical Cell Line Development - Reducing risk and decr...
Streamlining Biopharmaceutical Cell Line Development - Reducing risk and decr...Streamlining Biopharmaceutical Cell Line Development - Reducing risk and decr...
Streamlining Biopharmaceutical Cell Line Development - Reducing risk and decr...
Merck Life Sciences
 
The Future of Bioprocessing – What you need to know.
The Future of Bioprocessing – What you need to know.The Future of Bioprocessing – What you need to know.
The Future of Bioprocessing – What you need to know.
Merck Life Sciences
 
Promises and Challenges of Manufacturing and Testing Viral Producer Cell Lines
Promises and Challenges of Manufacturing and Testing Viral Producer Cell LinesPromises and Challenges of Manufacturing and Testing Viral Producer Cell Lines
Promises and Challenges of Manufacturing and Testing Viral Producer Cell Lines
Merck Life Sciences
 
Latest Updates in Biosafety Testing for Gene Therapy
Latest Updates in Biosafety Testing for Gene TherapyLatest Updates in Biosafety Testing for Gene Therapy
Latest Updates in Biosafety Testing for Gene Therapy
MilliporeSigma
 
Program - 3rd Annual Drug Delivery and Formulation Summit 2013, San Diego
Program - 3rd Annual Drug Delivery and Formulation Summit 2013, San DiegoProgram - 3rd Annual Drug Delivery and Formulation Summit 2013, San Diego
Program - 3rd Annual Drug Delivery and Formulation Summit 2013, San Diego
Mark Blendheim
 
The Butterfly Effect: How to see the impact of small changes to your ADC
The Butterfly Effect: How to see the impact of small changes to your ADCThe Butterfly Effect: How to see the impact of small changes to your ADC
The Butterfly Effect: How to see the impact of small changes to your ADC
MilliporeSigma
 
Webinar: Benefits of Monodisperse Activated PEGs in ADC Development
Webinar: Benefits of Monodisperse Activated PEGs in ADC DevelopmentWebinar: Benefits of Monodisperse Activated PEGs in ADC Development
Webinar: Benefits of Monodisperse Activated PEGs in ADC Development
MilliporeSigma
 
Excipients selection for high risk formulations Smita Rajput
Excipients selection for high risk formulations Smita RajputExcipients selection for high risk formulations Smita Rajput
Excipients selection for high risk formulations Smita Rajput
Merck Life Sciences
 

What's hot (18)

Overview of Global Regulatory Affairs for Gene Therapy 2019
Overview of Global Regulatory Affairs for Gene Therapy 2019Overview of Global Regulatory Affairs for Gene Therapy 2019
Overview of Global Regulatory Affairs for Gene Therapy 2019
 
Get Proactive With Your Stability Program
Get Proactive With Your Stability ProgramGet Proactive With Your Stability Program
Get Proactive With Your Stability Program
 
The Minute: Volume 11 Issue 1 - Winter 2011
The Minute: Volume 11 Issue 1 - Winter 2011The Minute: Volume 11 Issue 1 - Winter 2011
The Minute: Volume 11 Issue 1 - Winter 2011
 
Payload Core Product Line Accelerates ADC Clinical Timelines
Payload Core Product Line Accelerates ADC Clinical TimelinesPayload Core Product Line Accelerates ADC Clinical Timelines
Payload Core Product Line Accelerates ADC Clinical Timelines
 
Process Impurities: Don’t Let PEI or HCP Derail Your BioTherapy
Process Impurities: Don’t Let PEI or HCP Derail Your BioTherapyProcess Impurities: Don’t Let PEI or HCP Derail Your BioTherapy
Process Impurities: Don’t Let PEI or HCP Derail Your BioTherapy
 
TetraQ - Integrated Preclinical Drug Development Solutions Presentation
TetraQ - Integrated Preclinical Drug Development Solutions PresentationTetraQ - Integrated Preclinical Drug Development Solutions Presentation
TetraQ - Integrated Preclinical Drug Development Solutions Presentation
 
Upcoming USP 665 - Level of Characterization of Single-Use Systems Today and ...
Upcoming USP 665 - Level of Characterization of Single-Use Systems Today and ...Upcoming USP 665 - Level of Characterization of Single-Use Systems Today and ...
Upcoming USP 665 - Level of Characterization of Single-Use Systems Today and ...
 
A Molecule’s Journey – Breaking Down Roadblocks to Commercial Success
A Molecule’s Journey – Breaking Down Roadblocks to Commercial SuccessA Molecule’s Journey – Breaking Down Roadblocks to Commercial Success
A Molecule’s Journey – Breaking Down Roadblocks to Commercial Success
 
SMi Group's Drug Discovery 2018
SMi Group's Drug Discovery 2018SMi Group's Drug Discovery 2018
SMi Group's Drug Discovery 2018
 
Walter King Resume 2015
Walter King Resume 2015Walter King Resume 2015
Walter King Resume 2015
 
Streamlining Biopharmaceutical Cell Line Development - Reducing risk and decr...
Streamlining Biopharmaceutical Cell Line Development - Reducing risk and decr...Streamlining Biopharmaceutical Cell Line Development - Reducing risk and decr...
Streamlining Biopharmaceutical Cell Line Development - Reducing risk and decr...
 
The Future of Bioprocessing – What you need to know.
The Future of Bioprocessing – What you need to know.The Future of Bioprocessing – What you need to know.
The Future of Bioprocessing – What you need to know.
 
Promises and Challenges of Manufacturing and Testing Viral Producer Cell Lines
Promises and Challenges of Manufacturing and Testing Viral Producer Cell LinesPromises and Challenges of Manufacturing and Testing Viral Producer Cell Lines
Promises and Challenges of Manufacturing and Testing Viral Producer Cell Lines
 
Latest Updates in Biosafety Testing for Gene Therapy
Latest Updates in Biosafety Testing for Gene TherapyLatest Updates in Biosafety Testing for Gene Therapy
Latest Updates in Biosafety Testing for Gene Therapy
 
Program - 3rd Annual Drug Delivery and Formulation Summit 2013, San Diego
Program - 3rd Annual Drug Delivery and Formulation Summit 2013, San DiegoProgram - 3rd Annual Drug Delivery and Formulation Summit 2013, San Diego
Program - 3rd Annual Drug Delivery and Formulation Summit 2013, San Diego
 
The Butterfly Effect: How to see the impact of small changes to your ADC
The Butterfly Effect: How to see the impact of small changes to your ADCThe Butterfly Effect: How to see the impact of small changes to your ADC
The Butterfly Effect: How to see the impact of small changes to your ADC
 
Webinar: Benefits of Monodisperse Activated PEGs in ADC Development
Webinar: Benefits of Monodisperse Activated PEGs in ADC DevelopmentWebinar: Benefits of Monodisperse Activated PEGs in ADC Development
Webinar: Benefits of Monodisperse Activated PEGs in ADC Development
 
Excipients selection for high risk formulations Smita Rajput
Excipients selection for high risk formulations Smita RajputExcipients selection for high risk formulations Smita Rajput
Excipients selection for high risk formulations Smita Rajput
 

Similar to Faster Media, Faster Outcomes 11.17.2020

Intelligent Media Formulation Using Machine Learning
Intelligent Media Formulation Using Machine LearningIntelligent Media Formulation Using Machine Learning
Intelligent Media Formulation Using Machine Learning
Nucleus Biologics
 
Informatics & Methods in drug design
Informatics & Methods in drug designInformatics & Methods in drug design
Informatics & Methods in drug design
Theabhi.in
 
Internship Poster
Internship PosterInternship Poster
Internship Poster
Shruti Agarwal
 
P4 c2011 slides ekins
P4 c2011 slides ekinsP4 c2011 slides ekins
P4 c2011 slides ekins
Sean Ekins
 
Novoron I-Corps@NIH 121014
Novoron I-Corps@NIH 121014 Novoron I-Corps@NIH 121014
Novoron I-Corps@NIH 121014
Stanford University
 
Session 6 part 2
Session 6 part 2Session 6 part 2
Session 6 part 2
plmiami
 
MDC Connect: In-Silico Drug Design - what to do, what not to do - project dri...
MDC Connect: In-Silico Drug Design - what to do, what not to do - project dri...MDC Connect: In-Silico Drug Design - what to do, what not to do - project dri...
MDC Connect: In-Silico Drug Design - what to do, what not to do - project dri...
Medicines Discovery Catapult
 
Inserogen Lecture 4 Channels
Inserogen Lecture 4 ChannelsInserogen Lecture 4 Channels
Inserogen Lecture 4 Channels
Stanford University
 
Presentation for UMass Workshop
Presentation for UMass WorkshopPresentation for UMass Workshop
Presentation for UMass Workshop
Daisy LaFlamme
 
Emerging Challenges for Artificial Intelligence in Medicinal Chemistry
Emerging Challenges for Artificial Intelligence in Medicinal ChemistryEmerging Challenges for Artificial Intelligence in Medicinal Chemistry
Emerging Challenges for Artificial Intelligence in Medicinal Chemistry
Ed Griffen
 
Presentation for umass workshop final 2
Presentation for umass workshop final 2Presentation for umass workshop final 2
Presentation for umass workshop final 2
nanalaw
 
CBGW John Pollak
CBGW John PollakCBGW John Pollak
CBGW John Pollak
Genome Alberta
 
Social Listening for Scientists - BLA Case Study
Social Listening for Scientists - BLA Case StudySocial Listening for Scientists - BLA Case Study
Social Listening for Scientists - BLA Case Study
Masood Akhtar
 
Designing drug virtually case study
Designing drug  virtually case studyDesigning drug  virtually case study
Designing drug virtually case study
szarinammd
 
Cadd
CaddCadd
Cybele final presentation
Cybele final presentationCybele final presentation
Cybele final presentation
Stanford University
 
Chap2 CTPMR, 2nd Ed. 2016
Chap2 CTPMR, 2nd Ed. 2016Chap2 CTPMR, 2nd Ed. 2016
Chap2 CTPMR, 2nd Ed. 2016
Eric Dollins
 
Practical Drug Discovery using Explainable Artificial Intelligence
Practical Drug Discovery using Explainable Artificial IntelligencePractical Drug Discovery using Explainable Artificial Intelligence
Practical Drug Discovery using Explainable Artificial Intelligence
Al Dossetter
 
APT_Indigo FactSheet FINAL
APT_Indigo FactSheet FINALAPT_Indigo FactSheet FINAL
APT_Indigo FactSheet FINAL
Tim Calvert
 
SLAS Ultra-High-Throughput Screening Special Interest Group SLAS2017 Presenta...
SLAS Ultra-High-Throughput Screening Special Interest Group SLAS2017 Presenta...SLAS Ultra-High-Throughput Screening Special Interest Group SLAS2017 Presenta...
SLAS Ultra-High-Throughput Screening Special Interest Group SLAS2017 Presenta...
SLAS (Society for Laboratory Automation and Screening)
 

Similar to Faster Media, Faster Outcomes 11.17.2020 (20)

Intelligent Media Formulation Using Machine Learning
Intelligent Media Formulation Using Machine LearningIntelligent Media Formulation Using Machine Learning
Intelligent Media Formulation Using Machine Learning
 
Informatics & Methods in drug design
Informatics & Methods in drug designInformatics & Methods in drug design
Informatics & Methods in drug design
 
Internship Poster
Internship PosterInternship Poster
Internship Poster
 
P4 c2011 slides ekins
P4 c2011 slides ekinsP4 c2011 slides ekins
P4 c2011 slides ekins
 
Novoron I-Corps@NIH 121014
Novoron I-Corps@NIH 121014 Novoron I-Corps@NIH 121014
Novoron I-Corps@NIH 121014
 
Session 6 part 2
Session 6 part 2Session 6 part 2
Session 6 part 2
 
MDC Connect: In-Silico Drug Design - what to do, what not to do - project dri...
MDC Connect: In-Silico Drug Design - what to do, what not to do - project dri...MDC Connect: In-Silico Drug Design - what to do, what not to do - project dri...
MDC Connect: In-Silico Drug Design - what to do, what not to do - project dri...
 
Inserogen Lecture 4 Channels
Inserogen Lecture 4 ChannelsInserogen Lecture 4 Channels
Inserogen Lecture 4 Channels
 
Presentation for UMass Workshop
Presentation for UMass WorkshopPresentation for UMass Workshop
Presentation for UMass Workshop
 
Emerging Challenges for Artificial Intelligence in Medicinal Chemistry
Emerging Challenges for Artificial Intelligence in Medicinal ChemistryEmerging Challenges for Artificial Intelligence in Medicinal Chemistry
Emerging Challenges for Artificial Intelligence in Medicinal Chemistry
 
Presentation for umass workshop final 2
Presentation for umass workshop final 2Presentation for umass workshop final 2
Presentation for umass workshop final 2
 
CBGW John Pollak
CBGW John PollakCBGW John Pollak
CBGW John Pollak
 
Social Listening for Scientists - BLA Case Study
Social Listening for Scientists - BLA Case StudySocial Listening for Scientists - BLA Case Study
Social Listening for Scientists - BLA Case Study
 
Designing drug virtually case study
Designing drug  virtually case studyDesigning drug  virtually case study
Designing drug virtually case study
 
Cadd
CaddCadd
Cadd
 
Cybele final presentation
Cybele final presentationCybele final presentation
Cybele final presentation
 
Chap2 CTPMR, 2nd Ed. 2016
Chap2 CTPMR, 2nd Ed. 2016Chap2 CTPMR, 2nd Ed. 2016
Chap2 CTPMR, 2nd Ed. 2016
 
Practical Drug Discovery using Explainable Artificial Intelligence
Practical Drug Discovery using Explainable Artificial IntelligencePractical Drug Discovery using Explainable Artificial Intelligence
Practical Drug Discovery using Explainable Artificial Intelligence
 
APT_Indigo FactSheet FINAL
APT_Indigo FactSheet FINALAPT_Indigo FactSheet FINAL
APT_Indigo FactSheet FINAL
 
SLAS Ultra-High-Throughput Screening Special Interest Group SLAS2017 Presenta...
SLAS Ultra-High-Throughput Screening Special Interest Group SLAS2017 Presenta...SLAS Ultra-High-Throughput Screening Special Interest Group SLAS2017 Presenta...
SLAS Ultra-High-Throughput Screening Special Interest Group SLAS2017 Presenta...
 

Recently uploaded

Thornton ESPP slides UK WW Network 4_6_24.pdf
Thornton ESPP slides UK WW Network 4_6_24.pdfThornton ESPP slides UK WW Network 4_6_24.pdf
Thornton ESPP slides UK WW Network 4_6_24.pdf
European Sustainable Phosphorus Platform
 
Topic: SICKLE CELL DISEASE IN CHILDREN-3.pdf
Topic: SICKLE CELL DISEASE IN CHILDREN-3.pdfTopic: SICKLE CELL DISEASE IN CHILDREN-3.pdf
Topic: SICKLE CELL DISEASE IN CHILDREN-3.pdf
TinyAnderson
 
Equivariant neural networks and representation theory
Equivariant neural networks and representation theoryEquivariant neural networks and representation theory
Equivariant neural networks and representation theory
Daniel Tubbenhauer
 
Randomised Optimisation Algorithms in DAPHNE
Randomised Optimisation Algorithms in DAPHNERandomised Optimisation Algorithms in DAPHNE
Randomised Optimisation Algorithms in DAPHNE
University of Maribor
 
3D Hybrid PIC simulation of the plasma expansion (ISSS-14)
3D Hybrid PIC simulation of the plasma expansion (ISSS-14)3D Hybrid PIC simulation of the plasma expansion (ISSS-14)
3D Hybrid PIC simulation of the plasma expansion (ISSS-14)
David Osipyan
 
原版制作(carleton毕业证书)卡尔顿大学毕业证硕士文凭原版一模一样
原版制作(carleton毕业证书)卡尔顿大学毕业证硕士文凭原版一模一样原版制作(carleton毕业证书)卡尔顿大学毕业证硕士文凭原版一模一样
原版制作(carleton毕业证书)卡尔顿大学毕业证硕士文凭原版一模一样
yqqaatn0
 
molar-distalization in orthodontics-seminar.pptx
molar-distalization in orthodontics-seminar.pptxmolar-distalization in orthodontics-seminar.pptx
molar-distalization in orthodontics-seminar.pptx
Anagha Prasad
 
The binding of cosmological structures by massless topological defects
The binding of cosmological structures by massless topological defectsThe binding of cosmological structures by massless topological defects
The binding of cosmological structures by massless topological defects
Sérgio Sacani
 
Bob Reedy - Nitrate in Texas Groundwater.pdf
Bob Reedy - Nitrate in Texas Groundwater.pdfBob Reedy - Nitrate in Texas Groundwater.pdf
Bob Reedy - Nitrate in Texas Groundwater.pdf
Texas Alliance of Groundwater Districts
 
Eukaryotic Transcription Presentation.pptx
Eukaryotic Transcription Presentation.pptxEukaryotic Transcription Presentation.pptx
Eukaryotic Transcription Presentation.pptx
RitabrataSarkar3
 
Applied Science: Thermodynamics, Laws & Methodology.pdf
Applied Science: Thermodynamics, Laws & Methodology.pdfApplied Science: Thermodynamics, Laws & Methodology.pdf
Applied Science: Thermodynamics, Laws & Methodology.pdf
University of Hertfordshire
 
EWOCS-I: The catalog of X-ray sources in Westerlund 1 from the Extended Weste...
EWOCS-I: The catalog of X-ray sources in Westerlund 1 from the Extended Weste...EWOCS-I: The catalog of X-ray sources in Westerlund 1 from the Extended Weste...
EWOCS-I: The catalog of X-ray sources in Westerlund 1 from the Extended Weste...
Sérgio Sacani
 
在线办理(salfor毕业证书)索尔福德大学毕业证毕业完成信一模一样
在线办理(salfor毕业证书)索尔福德大学毕业证毕业完成信一模一样在线办理(salfor毕业证书)索尔福德大学毕业证毕业完成信一模一样
在线办理(salfor毕业证书)索尔福德大学毕业证毕业完成信一模一样
vluwdy49
 
mô tả các thí nghiệm về đánh giá tác động dòng khí hóa sau đốt
mô tả các thí nghiệm về đánh giá tác động dòng khí hóa sau đốtmô tả các thí nghiệm về đánh giá tác động dòng khí hóa sau đốt
mô tả các thí nghiệm về đánh giá tác động dòng khí hóa sau đốt
HongcNguyn6
 
Sharlene Leurig - Enabling Onsite Water Use with Net Zero Water
Sharlene Leurig - Enabling Onsite Water Use with Net Zero WaterSharlene Leurig - Enabling Onsite Water Use with Net Zero Water
Sharlene Leurig - Enabling Onsite Water Use with Net Zero Water
Texas Alliance of Groundwater Districts
 
Medical Orthopedic PowerPoint Templates.pptx
Medical Orthopedic PowerPoint Templates.pptxMedical Orthopedic PowerPoint Templates.pptx
Medical Orthopedic PowerPoint Templates.pptx
terusbelajar5
 
20240520 Planning a Circuit Simulator in JavaScript.pptx
20240520 Planning a Circuit Simulator in JavaScript.pptx20240520 Planning a Circuit Simulator in JavaScript.pptx
20240520 Planning a Circuit Simulator in JavaScript.pptx
Sharon Liu
 
NuGOweek 2024 Ghent programme overview flyer
NuGOweek 2024 Ghent programme overview flyerNuGOweek 2024 Ghent programme overview flyer
NuGOweek 2024 Ghent programme overview flyer
pablovgd
 
Oedema_types_causes_pathophysiology.pptx
Oedema_types_causes_pathophysiology.pptxOedema_types_causes_pathophysiology.pptx
Oedema_types_causes_pathophysiology.pptx
muralinath2
 
waterlessdyeingtechnolgyusing carbon dioxide chemicalspdf
waterlessdyeingtechnolgyusing carbon dioxide chemicalspdfwaterlessdyeingtechnolgyusing carbon dioxide chemicalspdf
waterlessdyeingtechnolgyusing carbon dioxide chemicalspdf
LengamoLAppostilic
 

Recently uploaded (20)

Thornton ESPP slides UK WW Network 4_6_24.pdf
Thornton ESPP slides UK WW Network 4_6_24.pdfThornton ESPP slides UK WW Network 4_6_24.pdf
Thornton ESPP slides UK WW Network 4_6_24.pdf
 
Topic: SICKLE CELL DISEASE IN CHILDREN-3.pdf
Topic: SICKLE CELL DISEASE IN CHILDREN-3.pdfTopic: SICKLE CELL DISEASE IN CHILDREN-3.pdf
Topic: SICKLE CELL DISEASE IN CHILDREN-3.pdf
 
Equivariant neural networks and representation theory
Equivariant neural networks and representation theoryEquivariant neural networks and representation theory
Equivariant neural networks and representation theory
 
Randomised Optimisation Algorithms in DAPHNE
Randomised Optimisation Algorithms in DAPHNERandomised Optimisation Algorithms in DAPHNE
Randomised Optimisation Algorithms in DAPHNE
 
3D Hybrid PIC simulation of the plasma expansion (ISSS-14)
3D Hybrid PIC simulation of the plasma expansion (ISSS-14)3D Hybrid PIC simulation of the plasma expansion (ISSS-14)
3D Hybrid PIC simulation of the plasma expansion (ISSS-14)
 
原版制作(carleton毕业证书)卡尔顿大学毕业证硕士文凭原版一模一样
原版制作(carleton毕业证书)卡尔顿大学毕业证硕士文凭原版一模一样原版制作(carleton毕业证书)卡尔顿大学毕业证硕士文凭原版一模一样
原版制作(carleton毕业证书)卡尔顿大学毕业证硕士文凭原版一模一样
 
molar-distalization in orthodontics-seminar.pptx
molar-distalization in orthodontics-seminar.pptxmolar-distalization in orthodontics-seminar.pptx
molar-distalization in orthodontics-seminar.pptx
 
The binding of cosmological structures by massless topological defects
The binding of cosmological structures by massless topological defectsThe binding of cosmological structures by massless topological defects
The binding of cosmological structures by massless topological defects
 
Bob Reedy - Nitrate in Texas Groundwater.pdf
Bob Reedy - Nitrate in Texas Groundwater.pdfBob Reedy - Nitrate in Texas Groundwater.pdf
Bob Reedy - Nitrate in Texas Groundwater.pdf
 
Eukaryotic Transcription Presentation.pptx
Eukaryotic Transcription Presentation.pptxEukaryotic Transcription Presentation.pptx
Eukaryotic Transcription Presentation.pptx
 
Applied Science: Thermodynamics, Laws & Methodology.pdf
Applied Science: Thermodynamics, Laws & Methodology.pdfApplied Science: Thermodynamics, Laws & Methodology.pdf
Applied Science: Thermodynamics, Laws & Methodology.pdf
 
EWOCS-I: The catalog of X-ray sources in Westerlund 1 from the Extended Weste...
EWOCS-I: The catalog of X-ray sources in Westerlund 1 from the Extended Weste...EWOCS-I: The catalog of X-ray sources in Westerlund 1 from the Extended Weste...
EWOCS-I: The catalog of X-ray sources in Westerlund 1 from the Extended Weste...
 
在线办理(salfor毕业证书)索尔福德大学毕业证毕业完成信一模一样
在线办理(salfor毕业证书)索尔福德大学毕业证毕业完成信一模一样在线办理(salfor毕业证书)索尔福德大学毕业证毕业完成信一模一样
在线办理(salfor毕业证书)索尔福德大学毕业证毕业完成信一模一样
 
mô tả các thí nghiệm về đánh giá tác động dòng khí hóa sau đốt
mô tả các thí nghiệm về đánh giá tác động dòng khí hóa sau đốtmô tả các thí nghiệm về đánh giá tác động dòng khí hóa sau đốt
mô tả các thí nghiệm về đánh giá tác động dòng khí hóa sau đốt
 
Sharlene Leurig - Enabling Onsite Water Use with Net Zero Water
Sharlene Leurig - Enabling Onsite Water Use with Net Zero WaterSharlene Leurig - Enabling Onsite Water Use with Net Zero Water
Sharlene Leurig - Enabling Onsite Water Use with Net Zero Water
 
Medical Orthopedic PowerPoint Templates.pptx
Medical Orthopedic PowerPoint Templates.pptxMedical Orthopedic PowerPoint Templates.pptx
Medical Orthopedic PowerPoint Templates.pptx
 
20240520 Planning a Circuit Simulator in JavaScript.pptx
20240520 Planning a Circuit Simulator in JavaScript.pptx20240520 Planning a Circuit Simulator in JavaScript.pptx
20240520 Planning a Circuit Simulator in JavaScript.pptx
 
NuGOweek 2024 Ghent programme overview flyer
NuGOweek 2024 Ghent programme overview flyerNuGOweek 2024 Ghent programme overview flyer
NuGOweek 2024 Ghent programme overview flyer
 
Oedema_types_causes_pathophysiology.pptx
Oedema_types_causes_pathophysiology.pptxOedema_types_causes_pathophysiology.pptx
Oedema_types_causes_pathophysiology.pptx
 
waterlessdyeingtechnolgyusing carbon dioxide chemicalspdf
waterlessdyeingtechnolgyusing carbon dioxide chemicalspdfwaterlessdyeingtechnolgyusing carbon dioxide chemicalspdf
waterlessdyeingtechnolgyusing carbon dioxide chemicalspdf
 

Faster Media, Faster Outcomes 11.17.2020

  • 1. Faster Media, Faster Outcomes Faster Media, Faster Outcomes 12/4/2020 // confidential
  • 2. 2 Faster Media, Faster Outcomes Previous webinar: Better Media, Better Outcomes (available to view on Nucleus Biologics’ website) Today: Faster Media, Faster Outcomes Future webinar: Intelligent Media Formulation Using Machine Learning 2 Faster Media, Faster Outcomes 12/4/2020 // confidential
  • 3. 3 Who We Are David Sheehan Founder and CEO Nucleus Biologics Roddy O’Connor, Ph.D Research Assistant Professor University of Pennsylvania Alex Klarer Head of CellTherapy Development BioCentriq David Smith Ph.D VPTechnical Operations Ori Biotech Faster Media, Faster Outcomes 12/4/2020 // confidential
  • 4. 4 September Webinar Recap Media Can Be a Competitive Advantage in Your Therapy Development Perceived Impediments to Custom Cost? Development time? Expertise? Faster Media, Faster Outcomes
  • 5. 512/4/2020 // confidential Custom Media vs. Proprietary Off-the-Shelf Media (POTS) Custom • Built based on ingredients specified by scientist. • Can start with common basal media formulation or be completely custom. • Will usually be optimized to the unique attributes of the therapy company’s ecosystem. POTS • Cell-specific media developed by media manufacturer. • Formula is secret both in composition and concentration. • Formula can only be augmented by the user at the point of manufacturing. Faster Media, Faster OutcomesFaster Media, Faster Outcomes
  • 6. 6 Media is a Critical Part of Your Therapy Ecosystem The dilemma of media choice in cell and gene therapy POTS Unknown ingredients, not your IP, sole sourced Fast regulatory, supposedly in- stock Custom media 6 month+ lead time, difficult to iterate Own the media, know every ingredient Faster Media, Faster Outcomes What is the Development Cycle and Cost? 12/4/2020 // confidential
  • 7. 7 Research POTS Suppliers Order and Delivery4 weeks Media Testing/Development w/ and w/Out Supplemental Reagents Order Additional Reagents to Test, and Delivery 4 weeks >> Ready to order, off the shelf media w/ additional reagents added at point of use Media Testing/Development w/ and w/out Supplemental Reagents 2 weeks 6 weeks 6 weeks Place Order – Delivery 2 Weeks Configuration and quoting Media Testing/Development Configuration and quoting 6 weeks Manufacturing Research Components4 weeks 20 weeks 6 weeks Manufacturing20 weeks 6 weeks Faster Media, Faster Outcomes Traditional Custom Media development cycle is 1 year Traditional Custom POTS 12/4/2020 // confidential
  • 8. 8 POTS Formulation - Trial and Error The number of conditions tested goes up with POTS because the formulations are unknown Companies Thermo Lonza Miltenyi Irvine Scientific R&D Systems STEMCELLTechnologies Cellgenix Reagents IL-2 IL-7 IL-15 Serum Physiologix HEPES Glutamine Faster Media, Faster Outcomes Thousands of test conditions to look at without knowing what is in the basal media you are using Testing 7 reagents creates 125 unique combinations and that doesn’t count concentration changes. Multiply that by the number of basal media tested 12/4/2020 // confidential
  • 9. Media Supplier Configuration and quoting Research Suppliers Small Lot Manufacturing 4 weeks Nucleus, a New Model for Custom POTS Research Components 2 weeks Media Testing/Development 6 weeks Configuration and quoting Small Lot Manufacturing 4 weeks Order and Delivery From Multiple Suppliers 4 weeks Media Testing/Development w/ and w/Out Supplemental Reagents Order Additional Reagents to Test, and Delivery 4 weeks 6 minutes Media Testing/Development 6 weeks >> Ready to order, scale production of custom media in any packaging required >> Ready to order, off the shelf media w/ additional reagents added at point of use Media Testing/Development w/ and w/out Supplemental Reagents It now takes the same amount of time to develop custom media as it does to create a formulation based on proprietary media 2 weeks 6 weeks 6 weeks Faster Media, Faster Outcomes 22 weeks
  • 10. OK, development time is equal but what about cost? 12/4/2020 10
  • 11. 11 Brand Media $/L Protein Reagents Total OpTmizer $166 $100 (serum at 5%) $20 (Il7, IL15) $286 XVivo Therapeak $182 $100 (serum at 5%) $20 (Il7, IL15) $302 Immunocult $320 $320 TexMACS $170 $100 (serum at 5%) $20 (IL7, IL15) $290 Average $299.50 Accounting for Media - $299.50/L for POTS Faster Media, Faster Outcomes 12/4/2020 // confidential
  • 12. 12 Base Medium (X-Vivo, OpTmizer) Reagents (IL-2, IL-15) Protein (HSA, Human AB) POT S NB-Lux $ $ $ $ $ $ $$166 $20 $100 $299.50 + Labor +Waste / Liter $189 / Liter @ 200L $470/ Litter @ 2L $ $ $$ Cost to Order Multiple known basal medias + reagents you choose Test multiple formulations quickly. Known basal media + protein + cytokines QC: POTS - each component Custom - final product Faster Media, Faster Outcomes 12/4/2020 // confidential
  • 13. 13 Development Costs Small Lot Custom materials are more expensive, but your labor time drives development costs 0K 20K 40K 60K 80K 100K 120K NB-Lux POTS Cost Can you go faster if you know the ingredients? Materials Labor Labor: Assume 22 weeks dev time at $100/hr Materials: $26K for Custom $18K for POTS Faster Media, Faster Outcomes 12/4/2020 // confidential
  • 14. 14 Lifecycle Costs – POTS 50% Higher Cost than Custom As You Go Into Commercial Production $M $2M $4M $6M $8M $10M $12M $14M Dev Phase 1 Phase 2 Phase 3 Commercial Low (#1000) Commercial High (#5000) CUMULAITVECOST NB-Lux Custom Thermo POTS Lonza POTS Faster Media, Faster Outcomes Most biotechs trade at 30X earnings. This is $120M of company value $4M/year 12/4/2020 // confidential
  • 15. 15 Summary So Far… • Development costs for media are dominated by labor hours not materials • Development time is the same for NB-Lux as it is for POTS • At scale production cost of NB-Lux custom media is 33% less than POTS • If you own the formula, it’s your IP and you control who manufactures it, the format, and second sources • Cost of a failed lot - how do you troubleshoot a failed lot if you don’t know what’s in your media? At scale production, you’re looking at millions of dollars of cost differential just for media. Faster Media, Faster Outcomes 12/4/2020 // confidential
  • 16. 12/4/2020 16 Case Study #1 Faster Media, Faster Outcomes
  • 17. 17 Custom Media is Required to Optimize your Cell Therapy Problem Statement: Inherent limitations with proprietary off-the-shelf media as the impact of individual components on CART-cell efficacy can’t be studied The Goal: The goal was to design medium specifically lacking a single amino acid to test its contribution to mitochondrial function in CART-cells Methods: Design medium lacking arginine using the NB-LUX platform. Supplement this medium with varying levels of 13C6 arginine Results: The final media was easily designed, cost-efficient, and yielded considerable insights into the role of arginine in CART-cell metabolic function Faster Media, Faster Outcomes 12/4/2020 // confidential
  • 18. 18 Cancer patient T cells removal from a patient 1 Genetic redirection ofT cells ex vivo expansion 2 3 Reintroduction of modifiedT cells 4 Generating CAR-T Cells for Cell-Based Therapies Faster Media, Faster Outcomes 12/4/2020 // confidential
  • 19. 19 α-ketoglutarate succinyl-CoA succinate fumarate citrate oxaloacetate L-malate acetyl-CoA IDH MD FH SD acetyl-CoApyruvate PD Glucose Citrate Acetyl CoA Palmitate TCA Cycle 13C5 Gln GlnCO2 13C5 Gln Using a [U-13C5]-Glutamine Tracer to Examine Glutamine Metabolism in T Cells Faster Media, Faster Outcomes 12/4/2020 // confidential
  • 20. 20 0 20 40 60 80 100 %labelinSuccinyl- CoA Untreated 13C5 gln Bulk T 13C5 gln CD4+ 13C5 Glutamine 0 20 40 60 80 100 M+0 M+1 M+2 %labelinacetyl-CoA pool Untreated Bulk T CD4+ CD8+ 13C5 Glutamine α-ketoglutarate succinyl-CoA succinate fumarate citrate oxaloacetate L-malate acetyl-CoA IDH MD FH SD Citrate Acetyl CoA Palmitate TCA Cycle 13C5 Gln GlnCO2 How can we optimize the medium for these studies? Representative data from O’Connor et al., 2018 Glutamine Supports Mitochondrial Function in Activated T Cells Faster Media, Faster Outcomes 12/4/2020 // confidential
  • 21. 21 SY5Y (1m M ) T cells (1m M ) T cells (4m M ) 0 20 40 60 80 100 %LabeledOrnithine 13C6 L-Arginine SY5Y (1m M ) T cells (1m M ) T cells (4m M ) 0 20 40 60 80 100 %LabeledOrnithine 13C6 L-Arginine Customized Medium Supports Our Efforts To Determine The Role of Amino Acids in CAR T-cell Metabolism Faster Media, Faster Outcomes 12/4/2020 // confidential
  • 22. 22 Custom Media is Required to Optimize Your Cell Therapy Conclusion: Identified the need to have media without certain components to test the impact on the effectiveness of the CART cells Solution: Order small lot Arginine-free media with ease (5 minutes) from NB-Lux and supplemented it with varying levels to test its role inT cells Impact: Performed experiments to show that higher levels play an important role in metabolic function inCART cells. Expand study to look at other amino acids. Long term expectation is an advanced formulation for enhanced CART cell potency. Faster Media, Faster Outcomes 12/4/2020 // confidential
  • 23. 12/4/2020 23 Case Study #2 Media forVaccines- Formulation to ordering Faster Media, Faster Outcomes
  • 24. 24 Xeno Free Vaccine Media Problem Statement: A biotech generating a novel vaccine was struggling to eliminate animal origin components from their media without affecting critical quality attributes. The Goal: The goal was to maintain proliferation and therapeutic potency with a simple xeno free media that if possible, also lowered the cost of production. Methods: Nucleus Biologics FormulationTeam through a combination of high throughput screening and experience-based component selection was able to create an optimized formulation within 2 cycles of testing. Results: The final media was AOF, equivalent or slightly better in proliferation and significantly lower cost. Formulation was transferred to NB-Lux for small lot ordering. Faster Media, Faster Outcomes 12/4/2020 // confidential
  • 25. 2512/4/2020 Xeno Free Vaccine Media - Results 2 step process – get rid of animal origin components and then optimize media by modifying amino acids and other component level changes Faster Media, Faster Outcomes
  • 26. 26 Developing Custom Media Enables Multifactor Analysis 0 0.5 1 1.5 2 2.5 3 Media A Media B Media C Media D RELATIVEYIELD POTS Simulated Results 0% HABS 2.5% HABS 5% HABS 10% HABS 0.0x Glutamine 0.5x Glutamine 1.0x Glutamine 1.5x Glutamine 0 0.5 1 1.5 2 2.5 0.0x Arginine 0.5x Arginine 1.0x Arginine 1.5x Arginine RelativeYield 0-0.5 0.5-1 1-1.5 1.5-2 2-2.5 Custom Media Simulated Results Faster Media, Faster Outcomes 12/4/2020 // confidential
  • 27. 27 Comparison of Approaches • Time to develop media was 3 months • Trial and error testing with POTS would have been same time • Removed animal components and optimized for critical quality attributes of customer • Formula now stored on NB-Lux and can order any size lot in any package configuration Faster Media, Faster Outcomes 12/4/2020 // confidential
  • 28. 28 NB-Lux as a Solution For Custom Media Start small! Use us as validation lots before you order big orders 28 Faster Media, Faster Outcomes
  • 29. 29 If NB Lux development doesn’t take longer, is less expensive, and is more optimized, what’s stopping you from ordering custom media? Q&A Session 29 Faster Media, Faster Outcomes Next Webinar: Intelligent self-guided formulation services 12/4/2020 // confidential
  • 30. 12/4/2020 30 Thank you! Connect with us LinkedIn: www.linkedin.com/company/nucleus-biologics Twitter: @nucleusbiologic Faster Media, Faster Outcomes